Lilrb4 Star-T Cells
Chronic Myelomonocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaCell therapyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 73/ 100
Competitive context
97 Active assets in the Chronic Myelomonocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pevonedistat Takeda | Phase 3 | BB |
Venetoclax Servier Bio-Innovation LLC | Phase 2/3 | BB |
Azacitidine The University of Hong Kong | Phase 3 | BB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | BB |
Astx727 Taiho Oncology, Inc. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Lilrb4 Star-T Cells is also rated in:
Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic LeukemiaDormant
CC
Indicative ·
47 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →